Silexion Therapeutics SLXN
NASDAQ SLXN
$0.26 -0.02 (-7.14%)
At close: Oct 2, 2026 · 4:00 PM EDT

Silexion Therapeutics (SLXN) Return on Equity [ROE] (2024 - 2026)

Updated

Silexion Therapeutics' Return on Equity [ROE] was -8333.13% in Q2 2026, down 7014.21 percentage points from -1318.92% a year earlier and down 7440.94 percentage points from the prior quarter.

Analysis

Silexion Therapeutics (SLXN) Return on Equity [ROE] (2024 - 2026) Analysis & Trends

From Q2 2024 onward, Silexion Therapeutics has reported Return on Equity [ROE] for 6 quarters.

  • Per Business Quant data, SLXN's Return on Equity [ROE] in the three quarters before Q2 2026 was -892.19% (Q1 2026), -248.68% (Q4 2025) and -260.59% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 25.32%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 7.21%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 84.40%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 21.39%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 83.75%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -18.38%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 4.97%
10 Silexion Therapeutics 178,711.77 -19.70 Mn - -8,333.13%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -8,333.13%
Mar 31, 2026 -892.19%
Dec 31, 2025 -248.68%
Sep 30, 2025 -260.59%
Jun 30, 2025 -1,318.92%
Jun 30, 2024 -610.78%
API Access

Silexion Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=SLXN&period=max&api_key=YOUR_API_KEY